The results of intramyocardial implantation of autologous bone marrow cells treated with erythropoietin in the surgical treatment of coronary artery disease with severe lesion of vessels

Aim. To assess safety and efficacy of intramyocardial implantation of autologous bone marrow cells treated with erythropoietin in surgery for coronary artery disease (CAD).

Materials and methods. Eighty patients with CAD with diffuse and (or) distal lesions of the right coronary artery were randomly assigned to two groups: patients of group 1 (n=40) underwent coronary bypass surgery, implantation of autologous bone marrow cells treated with erythropoietin into the lower wall of the left ventricle, patients of group 2 (control group, n=40) underwent bypass surgery of the left coronary artery. Evaluation of the clinical status, perfusion and contractility of the myocardium was performed initially, 6 and 12 months after surgery.

Results. Six months after the operation, we found more pronounced decrease of functional class (FC) of angina and improvement in the 6-min walk distance in the main group compared with the control group.

Twelve months after surgery, the severity of angina remained at the same level in both groups. In the control group, 45,2% of patients had FC I, 52,3% of patients did not have angina. In both groups, angina return was detected in 1 patient (FC III). According to the results of two-step myocardial scintigraphy with Technetril (Tc99), 6 months after surgery, a significant improvement in myocardial perfusion was observed. In the control group, after 6 months, no significant dynamics of perfusion of the lower wall of the left ventricle was detected.

Twelve months after the surgical treatment of the right coronary artery in patients from the group 1 revealed a decrease in the stress defect and the stable perfusion defect. In patients from the control only a significant stress defect was found to decrease.

Conclusion. The study demonstrated decrease of FCs, significant improvement in perfusion, functional state of the myocardium and 6-min walk distance in patients of group 1.

1. Boytsov SA, Zayratiants OV, Andreev ЕМ, et al. Comparison of coronary heart desease mortality in men and women age 50 years and older in Russia and USA. Russ J Cardiol. 2017;22(6): 100-7. (In Russ). doi:10.15829/1560-4071-2017-6-100-107.

2. Chernyavsky AM, Fomichev AV, Chernyavsky MA, et al. Comparative characteristics of the effectiveness of methods of indirect myocardial revascularization in surgery of ischemic heart disease. Pathology of blood circulation and cardiovascular surgery. 2012;17,1:16-9. (In Russ) doi: 10.21688/1681-3472-2013-1-15-20.

3. Zakharov YM. Cytotyre-tread functions of erythropoietin. Clinical nephrology. 2009;1:16-21. (In Russ).

4. Lipsic E, Schoemaker RG, van der Meer P, et al. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol. 2006 Dec 5; 48(11):2161-7 doi:10.1016/j.jacc.2006.08.031.

5. . Brunner S, Winogradov J, Huber BC, et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis. FASEB J. 2009 Feb;23(2):351-61. doi:10.1096/fj.08-109462.

6. Ward MR, Stewart DJ. Erythropoietin and mesenchymal stromal cells in angiogenesis and myocardial regeneration: one plus one equals three. Cardiovasc Res. 2008 Aug 1;79(3):357-9. doi:10.1093/cvr/cvn153.

7. Zhang DG, Zhang FM, Zhang YQ, et al. Erythropoietin enhances the therapy potency of autologous bone marrow stromal cells in a rat heart infarction model via phosphatidylinositol-3-kinase/Akt pathway. Cardiology. 2007;108(4):228-36.

8. Wang JA, Xie XJ, He H, Sun Y, Jiang J, et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Feb;34(2):107-10.

9. Lykov АР, Poveshchenko OV, Cherniavsky AM, et al. Phenotype of bone-marrow mononuclear cells before and after short-time precondition with erythropoietin from patients with ischemic heart failure. Russian Open Medical Journal. 2018;7,2:1-7. doi:10.15275/rusomj.2018.0202.

10. Copland IB, Jolicoeur EM, Gillis MA, et al. Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. Cardiovasc Res. 2008 Aug 1;79 (3):405-15. doi:10.1093/cvr/cvn090.